HIV

Walmart has opened 70 Specialty Pharmacies of the Community locations across the U.S. in June, and is expected to open 80 more in 11 states by the end of the year.

Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.

Cannabis may accentuate the effects of HIV on the brain or perhaps may mitigate them because of its anti-inflammatory properties.

The deal, initially tentative, was announced Friday between the administration and those challenging the Affordable Care Act mandate.

Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.

‘Yes, PrEP is very important and very useful, but its use is complemented extremely by HIV treatment, so you really have to do both,’ says researcher.

CDC researchers estimate an almost 50% decrease in those with uncovered costs associated with HIV preexposure prophylaxis (PrEP). More people who are PrEP eligible have insurance and the cost of PrEP has declined.

A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.

A Kaiser Permanente study shows a close link between HIV RNA levels and low CD4 counts and the risk of heart failure.

Stem cell transplants are not being proposed as treatments for HIV, but this case and a handful of others offer promising confirmation that HIV is not entirely incurable.

The known benefits of antiretroviral therapy (ART) in pregnant persons living with HIV outweigh the risks, which include low-birth weight and metabolic complications for the pregnant person, says the lead author of a review article ART and adverse outcomes published in the New England Journal of Medicine.

In their final thoughts, Eugene McCray, M.D., and Steven Peskin, M.D., MBA, FACP, share insights into unmet needs surrounding HIV treatment management.

Drs McCray and Peskin provide an overview of the CAPELLA trial.

Researchers report positive result from a phase 1 trial that show the presence of the antiviral medication in rectal tissue.

Treatment barriers inhibit optimal care for many patients diagnosed with HIV.

Dr. Peskin identifies the significance of payer support in the treatment landscape of MDR HIV.

Non–treatment-naïve patient considerations are explored by key opinion leaders.

Medical experts provide an overview of testing considerations for MDR HIV.

Steven Peskin, M.D., MBA, FACP, discusses considerations for payers when identifying patients at risk for drug-resistant HIV.

Health disparities in HIV treatment management are discussed by Drs Peskin and McCray.

Uptake of pre-exposure prophylaxis (PrEP) has been slow. A survey shows that safety and side effects are the top concerns.

Tulane University researchers are studying whether dysregulation of the oral microbiome might affect HIV outcomes. They are using rhesus monkeys and SIV infection as a model.